Immunovant, Inc. IMVT
37.04 USD +1.33 (+3.72%)
At closeNov 11, 2026, 4:00 PM EST
37.04 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
35.52 Day range 37.59
21.86 52-week range 45.42
- YTD
- +45.71%
- 1 year
- +61.82%
News
zacks.com Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the…
seekingalpha.com Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in…
zacks.com Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.
benzinga.com Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47 Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.
seekingalpha.com Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript Immunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant…
benzinga.com Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA).
benzinga.com Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.
marketbeat.com What Immunovant (IMVT) Said on Its Q2 Earnings Call Roivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 during its fiscal second-quarter earnings call. CEO Matt…
globenewswire.com Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially…
globenewswire.com Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com Immunovant Q1 2027 Earnings Call: Complete Transcript Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…